Abstract
It was with great interest that we read the article by Cravens et al. 1 on the incidence of propofol infusion syndrome. This is obviously an important question with significant clinical relevance. However, with all of the inherent limitations of a retrospective study as recognized by the authors, we find the interpretation and conclusion of the authors (“this study provides evidence that even in a non–critically ill population, prolonged high-dose propofol infusion is associated with otherwise unexplained metabolic acidosis in a significant number of patients”) to be inconsistent with the limited data presented.